Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anureet C. Copeland"'
Autor:
Anureet C. Copeland, Eliza M. Park, Janell Markey, Emily G. Holmes, Rebekah P. Nash, William A. Wood, Thomas C. Shea, Xianming Tan
Publikováno v:
Psychooncology
Autor:
Robert S. Wehbie, Anastasia Ivanova, Monique Clayton, Olga Frankfurt, Matthew C. Foster, Barbara Rapchak, Benyam Muluneh, James G. Xenakis, Anderson Black, Anureet C. Copeland
Publikováno v:
Leukemialymphoma. 60(7)
Tyrosine kinase inhibitors (TKIs), like imatinib, have radically changed the treatment of chronic myeloid leukemia (CML) since the early 2000s. Most CML patients will need prolonged treatment with ...
Autor:
Anureet C, Copeland, Carey K, Anders
Publikováno v:
Oncology (Williston Park, N.Y.). 32(10)
Adjuvant human epidermal growth factor receptor 2 (HER2)-directed treatment has changed dramatically over the past decade. Historically, the addition of 1 year of trastuzumab to adjuvant chemotherapy has significantly improved both disease-free survi
Autor:
James M. Coghill, Dominic T. Moore, Marcie L. Riches, Kimberly A. Kasow, Benjamin G. Vincent, Jonathan S. Serody, Andrew Sharf, William A. Wood, Thomas C. Shea, Anureet C. Copeland, Paul M. Armistead, Katarzyna Jamieson
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S222-S223
Autor:
Sascha A. Tuchman, William A. Wood, Ashley T. Freeman, Christopher D. Baggett, Thomas C. Shea, Anureet C. Copeland, Lei Zhou
Publikováno v:
Journal of Clinical Oncology. 35:10048-10048
10048 Background: Patients (pts) with multiple myeloma (MM) experience physical symptoms and complications from disease or treatment that include bone pain, fatigue, anorexia, and insomnia. However, the prevalence of psychiatric comorbidities and the
Autor:
Robert S. Wehbie, Matthew C. Foster, Monique Clayton, Barbara Rapchak, Anderson Black, Anureet C. Copeland
Publikováno v:
Blood. 126:3308-3308
Background: Poor adherence to tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) is one of the most powerful predictors of suboptimal responses. In fact, patients who adhere to ≤90% of imatinib (26.4% of patients in one seri